Equity Overview
Price & Market Data
Price: $50.98
Daily Change: -$2.89 / 5.66%
Daily Range: $50.91 - $54.81
Market Cap: $3,160,462,336
Daily Volume: 478,185
Performance Metrics
1 Week: -5.33%
1 Month: -2.49%
3 Months: 18.33%
6 Months: 32.37%
1 Year: 42.47%
YTD: 32.10%
Company Details
Employees: 126
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.